Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial
Egile Nagusiak: | , , , , , , , , , , , , , , |
---|---|
Formatua: | Conference item |
Argitaratua: |
American Society of Hematology
2016
|